AC Immune (NASDAQ:ACIU) Issues Earnings Results

AC Immune (NASDAQ:ACIU) released its quarterly earnings results on Wednesday. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.13, FiscalAI reports. The business had revenue of $18.67 million during the quarter, compared to analyst estimates of $9.59 million. AC Immune had a negative return on equity of 94.52% and a negative net margin of 245.32%.

AC Immune Price Performance

Shares of NASDAQ ACIU opened at $2.32 on Friday. The stock has a fifty day moving average price of $2.37 and a 200 day moving average price of $2.77. AC Immune has a 1-year low of $2.03 and a 1-year high of $4.00. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.87 and a quick ratio of 1.02. The company has a market cap of $236.11 million, a PE ratio of -4.30 and a beta of 1.59.

Insider Transactions at AC Immune

In other news, CEO Andrea Pfeifer sold 10,000 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $2.79, for a total value of $27,900.00. Following the completion of the sale, the chief executive officer owned 3,820,288 shares in the company, valued at approximately $10,658,603.52. This trade represents a 0.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.60% of the company’s stock.

Institutional Trading of AC Immune

A number of institutional investors have recently modified their holdings of the business. Marshall Wace LLP acquired a new position in AC Immune during the 4th quarter valued at approximately $586,000. Acadian Asset Management LLC increased its position in AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after acquiring an additional 172,796 shares during the period. Dimensional Fund Advisors LP raised its stake in AC Immune by 20.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock valued at $670,000 after acquiring an additional 36,353 shares in the last quarter. Sei Investments Co. acquired a new position in AC Immune during the 2nd quarter worth $51,000. Finally, Susquehanna International Group LLP bought a new position in AC Immune in the 3rd quarter valued at about $63,000. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ACIU has been the subject of several research reports. HC Wainwright restated a “buy” rating on shares of AC Immune in a research note on Wednesday, July 1st. BTIG Research reissued a “buy” rating and set a $8.00 target price on shares of AC Immune in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AC Immune in a report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, AC Immune presently has an average rating of “Hold” and an average price target of $7.50.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.